Literature DB >> 8385977

Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.

Y A Luqmani1, T Campbell, S Soomro, S Shousha, M C Rio, R C Coombes.   

Abstract

The expression of pS2 was examined histochemically in paraffin sections taken from biopsy material from patients diagnosed with ductal carcinoma in situ (DCIS). Often intense immunoreactivity, to an anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of DCIS, with significant positivity found in 63-67% of cases. In 15 samples analysed, we found a good correlation between pS2 expression and presence of progesterone receptor positive cells, but not with estrogen receptor. There was only a limited degree of correspondence between the cells staining with these anti-sera. Some pS2 positive cells were also seen in normal acini in areas adjacent to cancer but much less frequently in sections of normal breast from reduction mammoplasty. Most normal areas were negative, as were cysts. In benign proliferative conditions (seen in sections with and without DCIS) such as adenosis, sclerosing adenosis, mild and florid ductal epithelial hyperplasia, significant pS2 positivity was seen in about 50% of cases. These results suggest that there is a progressive increase in pS2 from normal to benign to cancer cells and that this gene is expressed in both the invasive and pre-invasive forms of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385977      PMCID: PMC1968340          DOI: 10.1038/bjc.1993.136

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry.

Authors:  N H Piggott; J A Henry; F E May; B R Westley
Journal:  J Pathol       Date:  1991-02       Impact factor: 7.996

2.  Treatment of screen detected ductal carcinoma in situ: a silver lining within a grey cloud?

Authors:  I S Fentiman
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

3.  Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues.

Authors:  N A Wright; R Poulsom; G W Stamp; P A Hall; R E Jeffery; J M Longcroft; M C Rio; C Tomasetto; P Chambon
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

4.  Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract.

Authors:  M C Rio; M P Chenard; C Wolf; L Marcellin; C Tomasetto; R Lathe; J P Bellocq; P Chambon
Journal:  Gastroenterology       Date:  1991-02       Impact factor: 22.682

5.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

Authors:  S A Fuqua; S D Fitzgerald; G C Chamness; A K Tandon; D P McDonnell; Z Nawaz; B W O'Malley; W L McGuire
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

6.  pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

Authors:  L H Schwartz; F C Koerner; S M Edgerton; J M Sawicka; M C Rio; J P Bellocq; P Chambon; A D Thor
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

7.  Suppression of transformation by and growth adaptation to low concentrations of glutamine in NIH-3T3 cells.

Authors:  A L Rubin
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

8.  Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma.

Authors:  B Theisinger; C Welter; G Seitz; M C Rio; R Lathe; P Chambon; N Blin
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

Authors:  J Bartkova; D M Barnes; R R Millis; W J Gullick
Journal:  Hum Pathol       Date:  1990-11       Impact factor: 3.466

10.  Expression of the pNR-2/pS2 protein in diverse human epithelial tumours.

Authors:  J A Henry; M K Bennett; N H Piggott; D L Levett; F E May; B R Westley
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more
  4 in total

1.  Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast.

Authors:  H Inaji; H Koyama; K Motomura; S Noguchi
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.

Authors:  S Detre; N King; J Salter; K MacLennan; J A McKinna; M Dowsett
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

3.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

Authors:  J A Foekens; H Portengen; M P Look; W L van Putten; B Thirion; M Bontenbal; J G Klijn
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

4.  1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells.

Authors:  Michel Aubé; Christian Larochelle; Pierre Ayotte
Journal:  Breast Cancer Res       Date:  2008-02-14       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.